Look Alike - Sound Alike Drugs

(Amphotericin B) lipid complex

Antifungal agent

quinapril

ACEi; heart failure, HTN

rabeprazole

PPI; GERD, duodenal/gastric ulcers, H. pylori

Diamox

diuretic/carbonic anhydrase inhibitor;

• (Dymelor)
• indication: Type 2 Diabetes Mellitus
• moa: sulfonylurea derivative that stimulates the islet cells to release insulin

• indication: otitis externa; effective as an antimicrobial agent
• -acetic acid and water
• -diluted form
• -relatively no harm
• -does not freeze or form crystals

• -is concentrated
• -less than 1% water content; pure acetic acid
• -very corrosive
• -forms crystals at cooler temps

• (donepezil)
• indication: Alzheimer's Disease
• moa: reversible acetylcholinesterase inhibitor leading to an increase in acetylcholine

• (alteplase, recombinant)
• indication: acute MI, cerebrovascular accident, PE, venous catheter occlusion
• moa: alteplase is a tissue plasmogen activator (TPA that enhances the conversion of plasmogen to plasmin by binding to fibrin, inititating fibrinolysis with limited systemic proteolysis

• (alteplase)
• indication: ONLY FDA approved thrombolytic agent approved for restoration of function to central venous access devices (CVADs); IV catheter clot; thromboembolic disorder

• (tenecteplase)
• indication: acute MI, PE, venous catheter occlusion
• moa: binds fibrin converting plasminogen to plasmin

• (pioglitazone)
• indication: Type 2 Diabetes Mellitus
• black box: may worsen congestive heart failure
• moa: a thiazolidinedione antidiabetic agent and potent peroxisome proliferator-activated receptor-gamma agonist; dependent on insulin for moa; increases insulin-dependent glucoses output, decreases hepatic glucose output

• (risedronate sodium)
• indication: osteoporosis, Paget's Disease, post-menopausal osteoporosis
• moa: bind to hydroxyapatite inhibiting osteoclast activity

• (DTaP; diphtheria, tetanus, acellular pertussis)
• i

• (dextroamphetamine/amphetamine)
• indication: ADHD, narcolepsy
• black box: risk of abuse/dependence
• moa: amphetamines block reuptake of norepinephrine and dopamine into the presynaptic neuron, and increase their release into the extraneuronal space

• (propranolol)
• indication: angina, capillary hemangioma, cardiac dysrhythmia, tremor, migraine
• black box: abrupt cessation increase chances of angina or MI
• moa: non-selective beta blocker

• (Kadcyla)
• indication: HER-2 pos metastatic breast cancer
• black box: hepatotoxicity, cardiotoxicity, pregnancy risk
• MOA: HER-2 antibody drug conjugate selective for HER-2 cells

• (Herceptin)
• indication: HER-2 metastatic breast cancer; Gastric cancer
• black box: cardiomyopathy, infusion rxn and pulmonary tox, pregnancy risk
• MOA: mediates antibody-dependent cellular cytotoxicity by inhibiting the overexpression of HER-2 proteins

(diltiazem)

indication: HTN, angina, A-fib

pilocarpine (Salagen)

indication: xerostomia

(hydromorphone)

indication: pain management; chronic pain

(Exalgo ER)

indication: pain management; chronic pain

(Dramamine)

indication: motion sickness; nausea

(Benadryl)

indication: allergic rxns, insomnia, motion sickness, antitussive, rhinitis, parkinsonism

(estrogen)

indication: menopause

(bupropion)

indication: major depressive disorder, seasonal affective disorder, smoking cessation

(propofol)

indication: general anesthesia

(fluconazole)

indication: candidiasis

(oxybutynin)

indication: overactive bladder

• (dobutamine)
• indication: cardiac decompensation

(dopamine)

indication: hemodynamic support (treat hypotension)

(Taxotere)

indication: Breast cancer, gastric adenocarcinoma, head n neck cancer, non-small cell lung cancer, prostate cancer

(paclitaxel)

indication: breast cancer, non-small cell lung cancer, ovarian cancer, kaposi sarcoma, bladder cancer, cervical

(doripenem)

indication: intra-abdominal infections, UTI, resp. tract infections

(acyclovir)

indication: HSV, Shingles

(doxorubicin)

• indication: multiple myeloma, kaposi sarcoma,
• ovarian cancer,

(paroxetine)

indication: OCD, anxiety

liposomal version; liposome makes it sustained release and more selective, thereby reducing cardiotoxicity

• laxative
• indication: constipation

stool softener

(cymbalta)

indication: diabetic neuropathic pain, fibromyalgia, anxiety, major depressive disorder

(prozac)

indication: depression, OCD, personality disorder, bulemia

(salicylic acid)

indication: acne, psoriasis, warts

(difluprednate)

indication: anterior uveitis (ophthalmic)

(cefadroxil)

indication: impetigo, pharyngitis, skin infections, UTIs

(tramadol)

indication: pain management

indication: lead poisoning; chelating agent

(venlafaxine)

(venlafaxine)

indication: depression, anxiety, panic disorder

(hydroxyurea)

indications: CML, sickle cell

(paliperidone)

indications: schizoaffective disorder

(etodolac)

indications: acute pain, osteoarthritis, RA

(isosorbide dinitrate)

indications: angina

(felodipine)

indications: HTN

• (Sitagliptin and Metformin)
• indication: Type 2 Diabetes Mellitus
• black box: metformin associated lactic acidosis
• moa: sitagliptin is a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor which slows the breakdown of endogenous incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) to maintain glucose homeostasis; metformin is a biguanide used to lower basal post-prandial plasma glucose by decreasing hepatic glucose production

• (Warfarin Sodium)
• indication: A-fib, MI, prosthetic valve, PE, thrombosis, venous thromboembolism
• black box: fatal bleeding
• moa: blocks regeneration of vitamin-K dependent clotting factors (2, 7, 9, 10 and proteins C and S)

• (sitagliptin)
• indication: Diabetes Mellitus Type 2
• moa: DPP-4 inhibitor; increases insulin release by protecting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP-1) from inactivation

• (carbidopa/levodopa)
• indication: Parkinson's disease
• moa: carbidopa inhibits decarboxylation of peripheral levodopa so it is available to transport across blood brain barrier; levodopa can then be converted to dopamine

• (Kaopectate [Bismuth subsalicylate])
• indication: diarrhea, heartburn, indigestion, nausea, upset stomach
• moa: stimulates absorption of fluids across intestinal wall; inhibits synthesis of prostaglandins and GI secretions, binds toxins produced by e.coli and Vibrio spp

• (Kaopectate [docusate calcium])
• indication: constipation
• moa: stool softener; anionic surfacant that stimulates intestinal secretion and increases the penetration of fluid into the stool

• (morphine sulfate)
• indication: chronic pain, pain unresponsive to non-narcotic analgesics
• black box: CNS depression w/ concomitant opioid or benzo use; acute or delayed resp depression when "Duramorph" admin via intrathecal or epidural; risk of overdose when substituted for inumorph or duramorph
• moa: opioid agonist, selective mu-receptor; primary action in brain; opioid induced hypotension due to histamine release

• (dexlansoprazole)
• indication: erosive esophagitis, heartburn, GERD
• moa: Selectively inhibits parietal cell membrane (H=,K+)-ATPase pumps

• (fluocinolone acetonide)
• indication: diabetic macular edema, disorder of skin, otitis externa, pruritusani, vulva, uveitis
• moa: low-to-medium potency synthetic corticosteroid; stimulates phospholipase A(2) inhibitory proteins and blocks the release of arachidonic acid

• (cephalexin)
• indications: prophylaxis-bacterial endocarditis, impetigo, osteomyelitis, otitis media, resp tract infec, strep pharyngitis, UTI
• moa: inhibits cell wall synthesis by binding penicillin binding proteins (PBPs) of dividing cells

• (levetiracetam)
• indication: myoclonic seizures; partial seizures; tonic-clonic and primary generalized seizures
• moa: unknown; does not involve excitatory or inhibitory neurotransmission

• (ketorolac)
• indicaton:extraction of cataract, short-term pain, seasonal allergic conjuctivitis
• black box: risk of fatal thrombotic cardiovascular events with increased use; contraindicated in CABG surgery; may cause peptic ulcers and GI bleeding; avoid use w/ other NSAIDs and renal insufficiency
• moa: NSAID that blocks prostaglandin complex formation and production

• (lopinavir/ritonovir)
• indication: HIV
• moa: lopinavir inhibits HIV protease cleavage of Gal-Pol polyprotein; ritonavir increases plasma levels of lopinavir by inhibiting CYP3A metabolism of lopinavir

• (ketamine)
• indication: general anesthesia, sedation, rapid sequence intubation
• moa: NMDA receptor antagonist

• (dolophine)
• indication: opiod detox, long term pain
• black box: QT prolongation, CNS depression with other opioids or benzos; neonatal withdrawal syndrome
• moa: synthetic opioid analgesic agonist at the mu-receptor; may also antagonize NMDA receptors

• (anakinra)
• indicaton: chronic intantile neurological, cutaneous and articular syndrome; rheumatoid arthritis
• moa: blocks activity of IL-1 by competitive;y inhibiting IL-1 type I receptor

• (clonazepam)
• indication: absence seizure w/ failed response to succinimides, Lennox-Gastaut syndrome, myclonic seizure, panic disorder, akinetic
• black box: concomitant use with opioids, benzos or other CNS depressants result in profound respiratory suppression, coma, death
• moa: may enhance GABA activity, which is the major inhibitory neurotransmitter int he CNS, decreasing the frequency, duration, and amplitude of seizures.

• (amikacin)
• indication: Bacterial (meningitis, sepsis, sepsis of newborn), Burn infection, cystic fibrosis/respiratory tract infection, infection of bone and joint infection, skin and/or subQ tissue, abdomen, peritonitis and SEVERE UTI and RTI
• moa: aminoglycoside that irreversibly binds to 30S-subunit proteins and 16S RNA; inhibits protein synthesis
• black box: neurotoxicity, ototoxicity, nephrotoxicity; increased risk with renal insufficiency

• (Lindane, Permethrin)
• indication: lice, scabies
• black box: seizures, neurotoxicity; contraindicated in children with Hx of seizures or <110 lbs
• moa: CNS stimulant causing convulsion/death in arthropods

Collagen drink